Sugi Predict

Sugi Predict / Compounds / SCHEMBL2384641

SCHEMBL2384641

SCHEMBL2384641

CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(C)=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STK3 Q13188 8/20 1.00
▸ STK4 Q13043 8/20 0.88
▸ EGFR P00533 10/20 0.84
▸ ERBB2 P04626 5/20 0.81
▸ BTK Q06187 2/20 0.78
▸ SRC P12931 2/20 0.78
▸ KDR P35968 2/20 0.78
▸ STK25 O00506 1/20 0.78
▸ MAP2K7 O14733 1/20 0.78
▸ CHEK1 O14757 1/20 0.78
▸ GAK O14976 1/20 0.78
▸ EPHB6 O15197 1/20 0.78
▸ ABCC4 O15439 1/20 0.78
▸ MAP3K13 O43283 1/20 0.78
▸ NUAK1 O60285 1/20 0.78
▸ STK17B O94768 1/20 0.78
▸ STK10 O94804 1/20 0.78
▸ PRKD3 O94806 1/20 0.78
▸ ABCB11 O95342 1/20 0.78
▸ MAP4K4 O95819 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL33532011 1.00 STK3 (1.00) STK3STK4EGFRERBB2BTK
SCHEMBL22419770 0.93 STK4 (1.00) STK3STK4EGFRERBB2BTK
SCHEMBL22419640 0.93 STK4 (0.90) STK3STK4EGFRERBB2BTK
SCHEMBL29801566 0.93 STK3 (0.86) STK3STK4EGFRERBB2BTK
SCHEMBL2387968 0.93 STK3 (0.86) STK3STK4EGFRERBB2BTK
SCHEMBL22419775 0.92 STK3 (0.85) STK3STK4EGFRERBB2BTK
SCHEMBL33531997 0.92 STK3 (0.85) STK3STK4EGFRERBB2BTK
SCHEMBL2384343 0.92 STK3 (0.85) STK3STK4EGFRERBB2BTK
SCHEMBL13826188 0.92 STK3 (0.85) STK3STK4EGFRERBB2BTK
SCHEMBL3476976 0.92 STK4 (0.88) STK3STK4EGFRERBB2BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112679473-B Lenatinib intermediate crystal, preparation method and application thereof 四川科伦药物研究院有限公司 2024-03-05 — — CN claimed
US-20260092046-A1 MALEATE SALTS OF (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF WYETH LLC (US) 2026-04-02 — — US disclosed
CN-117143077-A Lenatinib maleate and crystalline forms 惠氏有限责任公司 2023-12-01 — — CN disclosed
US-20230303523-A1 METHOD FOR PREPARING PYROTINIB SUZHOU FUSHILAI PHARMACEUTICAL CO., LTD (CN) 2023-09-28 — — US disclosed
CN-116715654-A Lenatinib maleate and crystalline forms 惠氏有限责任公司 2023-09-08 — — CN disclosed
CN-116715653-A Lenatinib maleate and crystalline forms 惠氏有限责任公司 2023-09-08 — — CN disclosed
US-11427560-B2 Composition and methods for inhibiting mammalian sterile 20-like kinase 1 THE SCRIPPS RESEARCH INSTITUTE (US) 2022-08-30 — — US disclosed
CN-106822127-B Lenalinib maleate and crystalline forms 惠氏有限责任公司 2022-07-29 — — CN disclosed
US-20210061784-A1 COMPOSITION AND METHODS FOR INHIBITING MAMMALIAN STERILE 20-LIKE KINASE 1 UNIVERSITÄT BREMEN (DE) 2021-03-04 — — US disclosed
CN-110204490-B Preparation method of disubstituted 4-chloroquinoline-3-carbonitrile derivative and bosutinib 新发药业有限公司 2021-01-01 — — CN disclosed
US-8022216-B2 Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof WYETH LLC (US) 2011-09-20 — — US disclosed
EP-2258698-A2 Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof Wyeth LLC (US) 2010-12-08 — — EP disclosed
EP-2258698-A2 Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof Wyeth LLC (US) 2010-12-08 — — EP disclosed
EP-2212311-A2 MALEATE SALTS OF (E)-N-{4-Ý3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO¨-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF Wyeth LLC (US) 2010-08-04 — — EP disclosed
US-20090176827-A1 MALEATE SALTS OF (E)-N--4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF WYETH (US) 2009-07-09 — — US disclosed
US-20090176827-A1 MALEATE SALTS OF (E)-N--4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF WYETH (US) 2009-07-09 — — US disclosed
US-20090176827-A1 MALEATE SALTS OF (E)-N--4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF WYETH (US) 2009-07-09 — — US disclosed
WO-2009052264-A2 MALEATE SALTS OF (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF WYETH (US) 2009-04-23 — — WO disclosed
WO-2009052264-A2 MALEATE SALTS OF (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF WYETH (US) 2009-04-23 — — WO disclosed
US-20060270668-A1 Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof WYETH (US) 2006-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210061784-A1 COMPOSITION AND METHODS FOR INHIBITING MAMMALIAN STERILE 20-LIKE KINASE 1 TESK2, TESK1, PRKACB STK3 456/4885STK4 852/4885EGFR 3953/4885
US-20060270668-A1 Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof HCCS, CYP3A7, QPCT STK3 444/4885STK4 838/4885EGFR 4068/4885
US-20260092046-A1 MALEATE SALTS OF (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF EGFR, MET, ERBB2 STK3 570/4885STK4 632/4885EGFR 1/4885
US-20090176827-A1 MALEATE SALTS OF (E)-N--4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF EGFR, ERBB4, ALK STK3 367/4885STK4 251/4885EGFR 1/4885
US-11427560-B2 Composition and methods for inhibiting mammalian sterile 20-like kinase 1 TESK2, TESK1, PRKACB STK3 456/4885STK4 852/4885EGFR 3953/4885
US-20230303523-A1 METHOD FOR PREPARING PYROTINIB JAK2, SRMS, JAK1 STK3 1563/4885STK4 1025/4885EGFR 934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.